secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001725160-23-000112
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports $392M cash; on track for azenosertib monotherapy dose, ASCO data
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $392M as of March 31, 2023; runway into Q2 2025.
- R&D expenses $48.6M (up $2.5M YoY); G&A expenses $16.4M (up $4.6M YoY), with lease impairment charges.
- On track to disclose azenosertib monotherapy dose in 1H 2023; positive Phase 1b chemo combo data in ovarian cancer at ASCO June 5.
- Appointed Diana Hausman, M.D. to Board of Directors; Funda Meric-Bernstam, M.D. to Scientific Advisory Board.
- ZN-d5 interim data in AL amyloidosis expected 2H 2023; Phase 1/2 combo with azenosertib in AML preliminary data also 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000112/0001725160-23-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000112/zntl-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer